Study guide

9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors

Key Takeaways Explain This Topic AI

STORE requires malignancies with behavior /2 or /3 at all sites, plus non-malignant (/0, /1) tumors of the meninges, brain, spinal cord, cranial nerves, pituitary, craniopharyngeal duct and pineal gland diagnosed on or after January 1, 2004.

Skin (C44) tumors with histologies 8000–8110 (including basal and squamous cell carcinoma) are not required, but melanoma, Merkel cell carcinoma, adnexal carcinomas and other histologies of the skin are.

CIN III and carcinoma in situ of the cervix, PIN III, and intraepithelial neoplasia III of the vulva, vagina, anus and larynx are not required by CoC; SEER and NPCR do require VIN III, VAIN III and AIN III.

LCIS (8520/2) alone is not required by CoC but is reportable to SEER and NPCR; since 2022, CoC also excludes high-grade dysplasia in adenomas (8210/2, 8211/2, 8261/2, 8263/2) at specified GI sites.

Pilocytic astrocytoma is coded 9421/1 (non-malignant) for all CNS sites from 2023 diagnoses; GIST and thymoma with behavior /3 are reportable from 2021; appendiceal LAMN (8480) is reportable from 2023.

Last updated: September 2026

Reportability depends on who is asking

The same tumor can be required by one standard setter and not another. A CoC-accredited hospital follows STORE for its NCDB cases and must still follow its state's reporting rules , which usually follow SEER and NPCR, for reporting to the central registry. On the exam, read the stem for "CoC," "SEER" or "central registry" and answer for that standard setter.

Behavior is the starting point

  • Behavior code Meaning General reportability
  • /0 Benign Reportable only for intracranial and CNS sites (see below)

/1 Uncertain or borderline Reportable only for intracranial and CNS sites. Borderline ovarian tumors and other non-CNS /1 tumors are not reportable.

  • /2 In situ Reportable at all sites, with the exceptions below
  • /3 Malignant Reportable at all sites, with the exceptions below
  • STORE 2025: tumors CoC programs must accession, abstract, follow and submit

Required: malignancies with behavior /2 or /3 at all sites, except :

Pilocytic astrocytoma and juvenile pilocytic astrocytoma. For cases diagnosed before 1/1/2023 these were reportable as 9421/3 at CNS sites other than the optic nerve. Beginning with 2023 diagnoses they are reported as 9421/1 at all CNS sites , so they now fall under the non-malignant CNS rules.

Carcinoid tumor of the appendix. Code 8240/1 became obsolete in 2015; appendix carcinoid (neuroendocrine) tumors are coded 8240/3 and are required.

Skin (C44._) with histologies 8000–8110 is not required. This range includes carcinoma NOS, squamous cell carcinoma and basal cell carcinoma of the skin. Skin cancers diagnosed before 2003 that were stage II–IV remain in the registry and continue to be followed.

Intraepithelial neoplasia grade III is not required: carcinoma in situ and CIN III (8077/2) of the cervix , PIN III (prostate), VIN III (vulva), VAIN III (vagina), AIN III (anus), LIN III (larynx), and squamous intraepithelial neoplasia.

Beginning with diagnoses on January 1, 2022 , these are not required: 8210/2 (adenomatous polyp, high-grade dysplasia) at specified stomach and small intestine sites (C16.0–C16.6, C16.8–C16.9, C17.0–C17.3, C17.8–C17.9); 8211/2 (tubular adenoma, high grade); 8261/2 (villous adenoma, high grade); 8263/2 (tubulovillous adenoma, high grade); and 8483/2 and 8484/2 (HPV-associated and HPV-independent adenocarcinoma in situ of the cervix).

Also required, or specifically addressed:

Non-malignant intracranial and CNS tumors (behavior /0 or /1) diagnosed on or after January 1, 2004 , at these sites: meninges (C70._), brain (C71._), spinal cord, cranial nerves and other CNS (C72._), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3).

GIST and thymoma with behavior /3 are reportable from January 1, 2021 . GIST or thymoma with multiple foci, metastasis or positive nodes must be coded /3.

Low-grade appendiceal mucinous neoplasm (LAMN, 8480) is reportable from January 1, 2023 , whether in situ or invasive.

LCIS (8520/2) alone is not reportable to CoC , to match AJCC 8th edition, but SEER and NPCR require LCIS . Follow your state's requirement for the central registry.

PI-RADS, BI-RADS and LI-RADS categories alone are not reportable for CoC. They become reportable when confirmed by a biopsy or a physician's statement.

Reportable-by-agreement cases are tumors CoC does not require but that the cancer committee or central registry asks the registry to collect, such as Class of Case 30 cases or pathology-only cases.

Where CoC and central registry rules differ

  • Tumor CoC (STORE) SEER and NPCR central registries
  • Skin SCC or BCC (C44, 8000–8110) Not required Not reportable
  • Cervical CIS and CIN III Not required Not reportable
  • PIN III Not required Not reportable
  • VIN III, VAIN III, AIN III Not required Reportable
  • LCIS (8520/2) Not required Reportable
  • High-grade dysplasia in adenomas at the listed GI sites (2022+) Not required Check SEER and state rules
  • Non-malignant CNS (/0, /1) at the listed sites Required (2004+) Required (2004+; Public Law 107-260)
  • Skin: what is excluded and what is not

The skin exclusion is defined by site and histology together . It covers only topography C44._ with histologies 8000–8110 . It therefore does not exclude:

Melanoma (8720–8790) of the skin, including melanoma in situ.

Merkel cell carcinoma (8247/3), adnexal and sweat or sebaceous gland carcinomas (for example, 8400/3, 8407/3, 8410/3), dermatofibrosarcoma protuberans , Kaposi sarcoma (9140/3), and cutaneous lymphomas such as mycosis fungoides (which follow the Hematopoietic Manual).

Squamous cell and basal cell carcinomas of genital sites that are not coded C44: vulva (C51), vagina (C52), penis (C60) and scrotum (C63.2). These are separate topography codes, so the C44 exclusion does not apply.

Mucosal sites such as the anal canal (C21.1) and the vermilion lip (C00.0–C00.2).

Perianal skin is coded C44.5 (skin of trunk), so a basal or squamous cell carcinoma of perianal skin is excluded.

Non-malignant CNS tumors in practice

Tumor Typical code Site Reportable?

  • Meningioma 9530/0 Cerebral meninges (C70.0) Yes
  • Atypical meningioma 9539/1 Meninges Yes
  • Vestibular schwannoma (acoustic neuroma) 9560/0 Acoustic nerve (C72.4) Yes

Schwannoma of a peripheral nerve in the arm 9560/0 Peripheral nerves (C47.1) No : not an intracranial or CNS site

Pituitary adenoma 8272/0 Pituitary gland (C75.1) Yes. A tumor diagnosed as a pituitary neuroendocrine tumor (PitNET) is coded 8272/3 according to the Solid Tumor Rules' malignant CNS table.

  • Craniopharyngioma 9350/1 Craniopharyngeal duct (C75.2) Yes
  • Pilocytic astrocytoma (2023+) 9421/1 Brain Yes, as a non-malignant CNS tumor

For CNS sites only, "tumor" and "neoplasm" preceded by a reportable ambiguous term are reportable, for example "consistent with pituitary tumor." "Mass" and "lesion" are not reportable terms, even for CNS.

Worked scenarios

Invasive SCC of the vulva: reportable. The vulva is C51, not C44, so the skin exclusion does not apply.

SCC in situ of the skin of the arm (Bowen disease): not reportable (C44 with histology 8070/2, in the 8000–8110 range).

Merkel cell carcinoma of the cheek: reportable (8247/3 is outside 8000–8110).

LCIS found at breast biopsy at a CoC hospital: not required for NCDB; report it to the state if the state requires LCIS, as SEER and NPCR registries do.

Tubular adenoma with high-grade dysplasia of the stomach (2026): not required by CoC (8211/2 is excluded from 2022). Check state rules.

Atypical meningioma: reportable as a non-malignant CNS tumor (9539/1), with Summary Stage 8.

Loading diagram... Reportability decision for a CoC-accredited program